Search research articles
Contact Us
Filters
Showing results (461-470 of 529) with videos related to
Page
of 53
Sort By:
Vaccine
|
July 29, 2017
Tularemia vaccine: Safety, reactogenicity, "Take" skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain - A phase 2 randomized clinical Trial
Mark J Mulligan, Jack T Stapleton, Wendy A Keitel, et al.
Journal of Medicinal Chemistry
|
July 14, 2021
Discovery of TAK-041: a Potent and Selective GPR139 Agonist Explored for the Treatment of Negative Symptoms Associated with Schizophrenia
Holly A Reichard, Hans H Schiffer, Holger Monenschein, et al.
Vaccine
|
October 17, 2024
Safety and immunogenicity of a ChAd155-vectored rabies vaccine compared with inactivated, purified chick embryo cell rabies vaccine in healthy adults
Varun K Phadke, Daniel J Gromer, Paulina A Rebolledo, et al.
Iscience
|
January 12, 2024
mRNA COVID-19 vaccine elicits potent adaptive immune response without the acute inflammation of SARS-CoV-2 infection
Ellie N Ivanova, Jasmine Shwetar, Joseph C Devlin, et al.
Medrxiv : the Preprint Server for Health Sciences
|
April 28, 2021
mRNA COVID-19 vaccine elicits potent adaptive immune response without the persistent inflammation seen in SARS-CoV-2 infection
Ellie N Ivanova, Jasmine Shwetar, Joseph C Devlin, et al.
Annals of Clinical and Translational Neurology
|
September 27, 2022
Hybrid and vaccine-induced immunity against SAR-CoV-2 in MS patients on different disease-modifying therapies
Ilya Kister, Ryan Curtin, Jinglan Pei, et al.
The Lancet. Infectious Diseases
|
June 18, 2026
Neutralising antibody responses to MPXV clades Ia, Ib, and IIb after infection or vaccination: a multicountry observational study
Jameson Crandell, Raianna F Fantin, Leonardo Pereira de Araújo, et al.
The Journal of Infectious Diseases
|
February 18, 1998
Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group
B S Graham, M J McElrath, R I Connor, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
April 2, 2021
Development of CVN424: A Selective and Novel GPR6 Inverse Agonist Effective in Models of Parkinson Disease
Nicola L Brice, Hans H Schiffer, Holger Monenschein, et al.
Frontiers in Immunology
|
September 14, 2023
Identification of immunodominant T cell epitopes induced by natural Zika virus infection
Christopher S Eickhoff, Krystal A Meza, Frances E Terry, et al.
Page
of 53
Search research articles
Search
Showing results (461-470 of 529) with videos related to
Sort By:
Page
of 53
Vaccine
|
July 29, 2017
Tularemia vaccine: Safety, reactogenicity, "Take" skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain - A phase 2 randomized clinical Trial
Mark J Mulligan, Jack T Stapleton, Wendy A Keitel, et al.
Journal of Medicinal Chemistry
|
July 14, 2021
Discovery of TAK-041: a Potent and Selective GPR139 Agonist Explored for the Treatment of Negative Symptoms Associated with Schizophrenia
Holly A Reichard, Hans H Schiffer, Holger Monenschein, et al.
Vaccine
|
October 17, 2024
Safety and immunogenicity of a ChAd155-vectored rabies vaccine compared with inactivated, purified chick embryo cell rabies vaccine in healthy adults
Varun K Phadke, Daniel J Gromer, Paulina A Rebolledo, et al.
Iscience
|
January 12, 2024
mRNA COVID-19 vaccine elicits potent adaptive immune response without the acute inflammation of SARS-CoV-2 infection
Ellie N Ivanova, Jasmine Shwetar, Joseph C Devlin, et al.
Medrxiv : the Preprint Server for Health Sciences
|
April 28, 2021
mRNA COVID-19 vaccine elicits potent adaptive immune response without the persistent inflammation seen in SARS-CoV-2 infection
Ellie N Ivanova, Jasmine Shwetar, Joseph C Devlin, et al.
Annals of Clinical and Translational Neurology
|
September 27, 2022
Hybrid and vaccine-induced immunity against SAR-CoV-2 in MS patients on different disease-modifying therapies
Ilya Kister, Ryan Curtin, Jinglan Pei, et al.
The Lancet. Infectious Diseases
|
June 18, 2026
Neutralising antibody responses to MPXV clades Ia, Ib, and IIb after infection or vaccination: a multicountry observational study
Jameson Crandell, Raianna F Fantin, Leonardo Pereira de Araújo, et al.
The Journal of Infectious Diseases
|
February 18, 1998
Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group
B S Graham, M J McElrath, R I Connor, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
April 2, 2021
Development of CVN424: A Selective and Novel GPR6 Inverse Agonist Effective in Models of Parkinson Disease
Nicola L Brice, Hans H Schiffer, Holger Monenschein, et al.
Frontiers in Immunology
|
September 14, 2023
Identification of immunodominant T cell epitopes induced by natural Zika virus infection
Christopher S Eickhoff, Krystal A Meza, Frances E Terry, et al.
Page
of 53